8-K: Soleno Therapeutics Achieves Profitability, Strong VYKAT XR Launch

Soleno Therapeutics reported strong fourth quarter and full-year 2025 financial results, achieving profitability and significant progress in the U.S. launch of VYKAT XR for Prader-Willi syndrome.

Summary

• Product revenue, net, from VYKAT XR reached $91.7 million for the fourth quarter and $190.4 million for the full-year ended December 31, 2025.
• The company achieved profitability with a positive net income of $20.9 million for the full-year 2025, a significant turnaround from a net loss of $(175.9) million in 2024.
• Generated $48.7 million of cash flow from operating activities in the fourth quarter of 2025.
• As of December 31, 2025, Soleno held $506.1 million in cash, cash equivalents, and marketable securities.
• Invested $100 million in an accelerated share repurchase program announced in November 2025.
• Since VYKAT XR's approval on March 26, 2025, through December 31, 2025, 1,250 patient start forms were received, 630 unique prescribers were engaged, and 859 patients were actively on drug.
• Over 185 million lives are covered for VYKAT XR, and patient start forms represent over 12% of the U.S. addressable market.
• Research and development expense decreased to $40.6 million for the full-year 2025 from $78.6 million in 2024, primarily due to reduced pre-commercial launch costs.
• Selling, general and administrative expense increased to $132.1 million for the full-year 2025 from $105.9 million in 2024, driven by commercial launch activities and increased headcount.
• A contingent liability of $20.3 million for Essentialis purchase price was estimated as of December 31, 2025, with a $7.0 million commercial milestone payment due in the first quarter of 2026.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as highly positive, reflecting a successful commercial launch and a significant turnaround to profitability, indicating strong market acceptance for VYKAT XR and robust financial management.

Positives

• Achieved full-year profitability with a net income of $20.9 million, a substantial improvement from a significant loss in the prior year.
• Generated strong product revenue of $190.4 million in the first nine months of VYKAT XR's commercial launch.
• Demonstrated robust cash flow from operating activities, with $48.7 million in Q4 2025.
• Maintained a strong balance sheet with $506.1 million in cash, cash equivalents, and marketable securities.
• Successfully launched VYKAT XR, evidenced by 1,250 patient start forms, 630 unique prescribers, and 859 active patients on drug within nine months.
• Secured broad market access with over 185 million lives covered for VYKAT XR.
• Initiated a $100 million accelerated share repurchase program, signaling confidence in the company's financial health and future prospects.

Risks

• Use of VYKAT XR is contraindicated in patients with known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
• Hyperglycemia, including diabetic ketoacidosis, has been reported with VYKAT XR use, requiring regular monitoring of fasting plasma glucose (FPG) and HbA1c.
• Risk of fluid overload, including severe reactions associated with edema, has been reported, necessitating monitoring for signs or symptoms of edema or fluid overload.
• VYKAT XR should be used with caution in patients with compromised cardiac reserve as it has not been studied in this population.
• Forward-looking statements are subject to risks, uncertainties, and assumptions, and actual results could differ materially from projections.

Future Outlook

The company plans to pursue regulatory approval for VYKAT XR in other territories, starting with the EU, and will begin evaluating diazoxide choline extended-release (DCCR) in additional high-need rare diseases to expand its development pipeline. Selling, general and administrative expenses are anticipated to increase as commercialization of VYKAT XR continues.

Management Comments

• "Our first year as a commercial organization has been an an outstanding success."
• "In just nine months, we received patient start forms representing over 12% of the U.S. VYKAT XR addressable market, reflecting both the strength of our world-class commercial team as well as the substantial disease burden that is addressed by VYKAT XR."
• "We are very pleased with the positive trajectory of our other leading indicators, including patient start forms, patients on active therapy, unique prescribers, and lives covered."
• "Looking ahead, with the U.S. VYKAT XR launch well underway, we plan to pursue regulatory approval in other territories, starting with the EU."
• "We will also begin to evaluate diazoxide choline extended-release (DCCR) in additional high-need rare diseases as we expand our development pipeline."
• "We have made excellent progress in 2025 and are excited for the year ahead."

Industry Context

StockSavvy.ai notes that the successful launch of VYKAT XR positions Soleno as a key player in the rare disease market, particularly for Prader-Willi syndrome, a niche with high unmet medical need. The rapid patient uptake and broad insurance coverage expansion suggest strong market acceptance, potentially setting a benchmark for other rare disease drug launches and demonstrating effective commercialization strategies in this specialized sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or projects to assess against global benchmarks.

Stakeholder Impact

• Shareholders are positively impacted by the company's achievement of profitability, strong revenue growth, robust cash position, and the $100 million accelerated share repurchase program.
• Patients with Prader-Willi syndrome benefit from the successful launch and increasing availability of VYKAT XR, addressing a significant unmet medical need.
• Employees benefit from the company's growth and successful commercialization efforts, potentially leading to increased stability and opportunities.

Next Steps

• Pursue regulatory approval for VYKAT XR in other territories, starting with the EU.
• Begin evaluating diazoxide choline extended-release (DCCR) in additional high-need rare diseases to expand the development pipeline.
• Make a $7.0 million commercial milestone payment in the first quarter of 2026.

Key Dates

Recommendation

The company has demonstrated exceptional commercial execution with VYKAT XR, achieving profitability in its first year of launch and generating substantial revenue. The strong patient uptake, broad insurance coverage, and robust cash position, coupled with a significant share repurchase program, indicate strong financial health and management confidence. Future expansion into the EU and pipeline development for other rare diseases provide additional growth catalysts, making this an attractive investment opportunity.

Keywords

Soleno Therapeutics, SLNO, VYKAT XR, diazoxide choline, Prader-Willi syndrome, PWS, hyperphagia, rare diseases, biopharmaceutical, financial results, drug launch, commercialization, profitability